Genomic Alterations in Cutaneous T-Cell Lymphoma

Mutations in genes involved in CTCL have implications for new therapeutic approaches.

Although many tumors have now been subjected to genomic profiling, cutaneous T-cell lymphoma (CTCL) has remained relatively unexplored, and currently no biomarkers have been identified to help determine therapy or outcome.

To address this issue, investigators performed a genomic-level study of CTCL mutations in 40 patients with stage IVA1–B disease and CTCL cells in the blood. Of these, 37 had undergone extracorporeal photopheresis. The mean time from disease diagnosis to CTCL sampling was 2.5 years.

A combination of exome sequencing and RNA sequencing confirmed that TP53 deletions or mutations were the most common alteration, with a mean of 63 total single nucleotide variants per tumor sample, dominated by UVB signature C→T mutations. In con…

Reviewing Author

Kenneth Y. Tsai, MD, PhD

Disclosures

Grant / Research support American Association for Cancer Research – Landon Foundation; National Institutes of Health/National Cancer Institute; Cancer Prevention Research Institute of Texas

Editorial BoardsJournal of the American Academy of Dermatology

Kenneth Y. Tsai, MD, PhD

Disclosures

Grant / Research support American Association for Cancer Research – Landon Foundation; National Institutes of Health/National Cancer Institute; Cancer Prevention Research Institute of Texas

Editorial BoardsJournal of the American Academy of Dermatology

Genomic Alterations in Cutaneous T-Cell Lymphoma

Topics

Reviewing Author